Intelligence Feed event · Policy · 2026-09-09

    CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients Aged 2+

    Question

    CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients Aged 2+

    Direct answer

    CRISPR Therapeutics received FDA approval for a label expansion of its gene-editing therapy Casgevy, extending treatment eligibility to pediatric patients aged two and older. The expanded indication follows Q2 commercial traction where Casgevy sales increased 78% sequentially to $76 million.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-09
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients Aged 2+”, revision 1, evidence through 2026-09-09. https://marketontology.com/market-events/2026-09-09/crispr-therapeutics-expands-casgevy-label-to-pediatric-patients-aged-2-f12277

    POLICY
    CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients Aged 2+
    CRISPR Therapeutics received FDA approval for a label expansion of its gene-editing therapy Casgevy, extending treatment eligibility to pediatric patients aged two and older. The expanded indication follows Q2 commercial traction where Casgevy sales increased 78% sequentially to $76 million.
    CRSPVRTX
    Impact
    70
    SEP 9
    SIG
    88%
    CRSPVRTX
    CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients Aged 2+
    CRISPR Therapeutics received FDA approval for a label expansion of its gene-editing therapy Casgevy, extending treatment eligibility to pediatric patients aged two and older. The expanded indication follows Q2 commercial traction where Casgevy sales increased 78% sequentially to $76 million.
    → FDA pediatric label expansion for Casgevy widens the eligible addressable patient population, lifting commercial revenue expectations for CRSP and partner VRTX.
    Impact
    CRISPR Therapeutics received FDA approval for a label expansion of its gene-editing therapy Casgevy, extending treatment eligibility to pediatric patients aged two and older. The expanded indication follows Q2 commercial traction where Casgevy sales increased 78% sequentially to $76 million.
    Affected
    CRSPVRTX
    Transmission
    FDA pediatric label expansion for Casgevy widens the eligible addressable patient population, lifting commercial revenue expectations for CRSP and partner VRTX.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    CRSPcommercial addressable market expansion and sales royalty accelerationUp1-4wFDA approved Casgevy pediatric label expansion; Q2 product sales reached $76M.
    VRTXcommercial collaboration revenue growth from expanded therapy reachUp1-4wVertex co-develops and commercializes Casgevy.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    VRTXUpdisagreed521.12 2026-09-09-1.26%-1.51%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month